This study was aimed to evaluate demographic, clinical, patients with normal ALT levels, and available data are conflicting. ## histological, and virological characteristics of 46 hepatitis C virus (HCV) carriers with persistently normal alanine trans- The aim of this study was to evaluate demogr
Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels
β Scribed by Masafumi Naito; Norio Hayashi; Hideki Hagiwara; Naoki Hiramatsu; Akinori Kasahara; Hideyuki Fusamoto; Takenobu Kamada
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 604 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
W e studied hepatitis C virus carriers with normal liver function to evaluate the histological features of their livers and the replicative levels of hepatitis C Virus. Liver biopsies were performed in 22 hepatitis C
The hepatitis C virus (HCV) was recently identified (l), and the precise serodiagnosis of chronic HCV infection is now possible by use of the second generation
π SIMILAR VOLUMES
HLA DR13 may be closely associated with this low activity of hepatitis among HCV carriers.
Viral recurrence is universal after transplantation for hepatitis C infection. This may lead to difficulties in differentiating allograft dysfunction caused by chronic rejection from hepatitis C virus (HCV) recurrence. Cases of severe cholestatic hepatitis have also been reported in conjunction with
The role of alcohol intake in the occurrence of severe liver disease in chronic hepatitis C virus (HCV) carriers is still debated. A cross-sectional study has been conducted in 233 chronic hepatitis C virus carriers. Weekly self-reported alcohol consumption (SRAC) was evaluated, serum HCV RNA levels
surface antigen (HBsAg) but also in patients with "resolved" HBV infection. 5,6 In a retrospective analysis of lymphoma patients who were HBsAg-negative and anti-HBV core antigen (anti-HBc) positive, 5 of the 21 patients who received chemotherapy plus rituximab, an anti-CD20 antibody, developed hepa